$EVLV

Evolv Technologies Holdings, Inc. Q2 2026 Earnings Call Summary

Evolv Technologies Holdings reported 34% Q2 2026 revenue growth, citing new customer acquisition and completion of a direct fulfillment transition. Management raised full-year 2026 revenue guidance to 23% to 27% growth, expects over 10,000 units deployed by year-end, and remains cash-flow positive while potentially investing $2m to $4m in inventory safety stock.

Original reporting
Published Aug 13, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 11:58 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evolv Technologies Holdings, Inc. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$EVLVBullishMed
01

Why it matters

Traders can update EVLV’s 2026 revenue and deployment expectations based on the raised guidance and the stated drivers (direct fulfillment transition, hardware-enabled subscription model, and customer adoption breadth). The key trade-off is a temporary gross margin headwind from Gen2 transition costs and higher immediate hardware cost recognition under purchase subscriptions.

02

Market read

Guidance raise plus detailed unit-to-ARR divergence and Gen2 transition cost/mix effects create a clear near-term narrative for EVLV’s revenue quality and margin trajectory.

03

What to watch

Semiconductor supply constraints and Gen2 upgrade costs are acknowledged; if supply tightens or Gen1 redeployment ARPU underperforms, the margin and ARR divergence could widen.

Relevance 7/10Novelty 6/10Timing: today’s earnings call summary, pre-market positioning for EVLV

Background

The piece summarizes Evolv Technologies Holdings’ Q2 2026 earnings call, focusing on growth drivers, Gen2 Express transition, subscription mix, and 2026 outlook assumptions.

Company-level read

Ticker impact

$EVLVBullishMedium confidence
Context

Evolv raised full-year 2026 revenue guidance to 23% to 27% growth and expects cash flow positive, citing subscription mix and deployments.

Expected impact

Likely positive bias for EVLV shares on guidance credibility, but investors may scrutinize temporary gross margin headwinds from Gen2 and purchase-subscription mix.

Evidence & confidence

The article provides specific, time-bound guidance changes (revenue growth range, unit deployments, cash flow positivity) plus quantified mix shifts (purchase subscriptions 60% vs 55%) and margin offsets (pricing and efficiencies vs Gen2 upgrade and component costs).

Market effects

Reinforces demand durability for weapons detection and AI screening in education and corporate settings, potentially supporting sentiment for adjacent public-safety tech names.

Notes early international progress starting with Canada, suggesting incremental expansion narrative beyond the US.

Limited direct global macro linkage, but Gen2 manufacturing and semiconductor supply constraints highlight broader hardware supply-chain sensitivity.

Counterpoint

Raised revenue guidance may be offset by near-term gross margin pressure from purchase-subscription mix and Gen2 refurbishment costs, so upside could be more revenue than profitability.

Key entities

  • Evolv Technologies Holdings, Inc.

    Subject of the earnings call summary, providing raised 2026 revenue guidance, deployment expectations, and margin/cash flow outlook.

  • Plexus

    Onboarded as a global contract manufacturing partner to scale production and potentially reduce bill of materials costs.

Related articles

$EVLVHigh

Evolv Technologies Holdings, Inc. (EVLV): Results of Operations and Financial Condition

Evolv Technologies Holdings, Inc. (EVLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Evolv Technology Reports Second Quarter Financial Results — Company Adds 70 New Customers — — Company Raises Growth Estimates for 2026 — • Q2'26 Revenue of $43.8 million, up 34% year-over-year • Q2'26 Ending ARR 1 of $132.7 million, up 20% year-over-year • Q2'26 Net

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.

$ORCLMedAI 8/10

Oracle’s AI Earnings Story Is Improving, but the Cash Flow Test Remains

Oracle (ORCL) reported strong Q4 earnings with 21% revenue growth and raised its profit forecast. Morgan Stanley increased its price target to $210, citing improved GPUaaS margins. However, the company faces cash flow pressure due to high capital expenditures for AI infrastructure, with free cash flow at negative $23.7 billion. Hedge funds remain invested, with Fisher Asset Management increasing its stake.

$AVGOMedAI 9/10

Broadcom’s AI Forecast Suggests Hyperscalers Want More Than Just Nvidia GPUs

Broadcom (AVGO) raised its AI chip revenue forecast to $115B for FY2027, up from $100B, and expects $230B in FY2028. This reflects Big Tech's demand for custom chips and networking components, reducing reliance on Nvidia (NVDA). KeyBanc reiterated an Overweight rating and $575 price target for AVGO. AVGO's Q3 revenue rose 86% YoY to $29.6B, but Q4 guidance was slightly below expectations. Hedge funds hold positions in both AVGO and NVDA, with Fisher Asset Management among the top holders.